Real-World Evidence Europe at eyeforpharma Barcelona

Memo

Real-World Evidence (RWE) is coming of ageFrom the way we discover treatments, to the nature of development and our understanding of what "value" really means - RWE is our purest reflection of value, and is rightly having seismic impact across the whole value chain. With the need for more advanced market access systems, more effective commercial models and newly revitalised drug development, RWE is growing up. Whilst uncertainty around regulatory and access authority decision-making must be overcome, RWE can deliver new life to decision-making throughout the product lifecycle. eyeforpharma Barcelona (March 31st - April 2nd) is the only event that brings together all key RWE stakeholders and decision-makers, plus thousands more health innovators together to spark new ideas and collaborations. 4 essential RWE and Big Data themes for 2020: Widen your RWE horizonCapitalise on emerging regulatory acceptance to increase access, better prove effectiveness and drive development decision-making Achieve Greater AccessDemonstrate drug value with increased certainty to enable more progressive market access agreements with payers Harness Technological MaturityFind new levels of insight through AI-driven analysis and dissemination, plus new medical-grade RWD devices and wearables Drive RWE AdoptionBuild trust in RWE by fostering higher level of data quality and consistency across health systems URLs:Tickets: https://go.evvnt.com/547457-0?pid=5569 Brochure: https://go.evvnt.com/547457-3?pid=5569  Date and Time: On Tuesday March 31, 2020 at 8:30 am ends Thursday April 02, 2020 at 3:00 pm Venue details: Centre de Convencions Internacional de Barcelona, 11-14 Plaça de Willy Brandt, Barcelona, Catalunya, 08019, Spain Prices:Pharma Silver Pass: EUR 1999.0,Solution Provider Silver Pass: EUR 2399.0 Speakers: Michael Seewald VP, Global Head, Real World Evidence Novartis, Chris Boone VP, Global Medical Epidemiology and Big Data Analysis Pfizer, Anjan Chatterjee VP, Real World Evidence - COE, Epidemiology and Big Data Boehringer Ingelheim, Janet Valentine Director of the CPRD CPRD, Nicola Bedlington Special Advisor European Patients Forum, Vignesh Rajah VP, Europe Area Medical Director, and EU Oncology Medical Integration Lead GSK, Michael Lees Head of RWE and Clinical Innovation Hub, Global Product Value and Access Takeda, Victoria Williams Vice President, Respiratory Medicine Commercialisation Leader GSK, Giuseppe Rosano Member CVWP EMA, Sam Hariry Head of Clinical Strategy and Operations Novartis, Richard Stephens Patient Advocate NCRI, Nigel Hughes Scientific Director Janssen, Wim Goettsch Special Advisor HTA; Affiliate Associate Professor International Collaboration in HTA, Universiteit Utrecht ZINL, Pam Bacon Executive Director, Global Medical Affairs Celgene, Abhimanyu Verma Lead, Applied Technology Innovation Novartis, Pall Jonsson Associate Director, Science Policy and Research NICE, Aida Ponce Privacy Officer and Senior Researcher ETUI, Adam Higgins Senior Director, Digital Health, Patient and Value Solutions AstraZeneca, Tarry Ahuja RWE Lead and Manager, Policy and Product Development Canadian Agency for Drugs and Technology in Health